Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

@article{Portenoy2012NabiximolsFO,
  title={Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.},
  author={Russell K. Portenoy and Elena Doina Ganae-Motan and Silvia Allende and Ronald H Yanagihara and Lauren A Shaiova and Sharon M. Weinstein and Robert A McQuade and Stephen D Wright and Marie T. Fallon},
  journal={The journal of pain : official journal of the American Pain Society},
  year={2012},
  volume={13 5},
  pages={438-49}
}
UNLABELLED Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Nabiximols (Nabiximols is the U.S. Adopted Name [USAN] for Sativex [GW Pharma Ltd, Wiltshire, U.K.], which does not yet have an INN), a novel cannabinoid formulation, is undergoing investigation as add-on therapy for this population. In a randomized, double-blind, placebo-controlled, graded-dose study, patients with advanced cancer and opioid-refractory pain received placebo… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Adjuvant analgesics in painmanagement

  • D Lussier, RK Portenoy
  • 2010
2 Excerpts

Interaction of the cannabinoid and opioid systems in themodulation of nociception

  • SP Welch
  • Int Rev Psychiatry
  • 2009
1 Excerpt

Cannabinoids and multiple sclerosis

  • RK Portenoy, P Lesage
  • Mol Neurobiol
  • 2007

Similar Papers

Loading similar papers…